Generics access legislation
This article was originally published in The Tan Sheet
Executive SummaryThe "Preserve Access to Affordable Generics Act" (S 316) has been approved by the Senate Judiciary Committee, according to a Feb. 15 announcement. The bill prohibits marketers of proprietary pharmaceuticals from paying generic drug companies to delay introduction of generic versions of drugs. Sen. Herb Kohl, D-Wis., et al. introduced the bill Jan. 17 to "support the purpose and intent of antitrust law by prohibiting anticompetitive agreements and collusion in the pharmaceutical industry," and to "clarify the law to prohibit payments from brand name generic drug manufacturers with the purpose to prevent or delay the entry of competition from generic drugs," according to the bill's text. The legislation also would require FTC to conduct a study on the prevalence in the pharmaceutical industry of anticompetitive agreements or other practices contrary to antitrust laws...
You may also be interested in...
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.